Compare RNAZ & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RNAZ | BGLC |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | United States | Malaysia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6M | 4.9M |
| IPO Year | 2021 | 2019 |
| Metric | RNAZ | BGLC |
|---|---|---|
| Price | $5.16 | $2.45 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 44.5K | ★ 59.6K |
| Earning Date | 04-15-2026 | 04-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 45.78 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $7,424,911.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.82 | $1.07 |
| 52 Week High | $20.99 | $15.19 |
| Indicator | RNAZ | BGLC |
|---|---|---|
| Relative Strength Index (RSI) | 33.76 | 67.94 |
| Support Level | $3.82 | $2.06 |
| Resistance Level | $6.30 | $2.73 |
| Average True Range (ATR) | 0.76 | 0.31 |
| MACD | 0.06 | 0.05 |
| Stochastic Oscillator | 35.48 | 94.48 |
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
BioNexus Gene Lab Corp is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (Chemrex) and MRNA Scientific Sdn. Bhd. (MRNA Scientific). Chemrex is engaged in the distribution of chemical raw materials, mainly for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management. Trading of industrial chemicals- Includes trading of industrial chemicals. Provision for genomic screening services- includes in commercializing proprietary blood-based diagnostic test for early disease detection. Investment holding- Investment holding, are its segments.